Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29281367 | 0.97 | CYP3A4 (0.30) | CYP3A4TSHRTDP1 | |
| SCHEMBL2089198 | 0.81 | — | — | |
| SCHEMBL19433235 | 0.69 | NMT1 (0.36) | — | |
| SCHEMBL898962 | 0.69 | TSHR (0.52) | TSHR | |
| SCHEMBL24617 | 0.64 | — | — | |
| SCHEMBL417479 | 0.60 | — | — | |
| SCHEMBL14344272 | 0.57 | — | — | |
| Ethylene SCHEMBL27335704 | 0.57 | TDP1 (0.41) | CYP3A4TSHRTDP1 | |
| Lithium Ion SCHEMBL31615957 | 0.55 | CYP3A4 (0.33) | CYP3A4TSHRTDP1 | |
| Potassium Ion SCHEMBL22802578 | 0.55 | CYP3A4 (0.33) | CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163778-B2 | Pyridines as FBPase inhibitors for treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2009-06-04 | — | — | US | disclosed |
| WO-2005003103-A2 | 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003103-A2 | 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | FBP1, PDXK, G6PC1 | CYP3A4 306/4885TSHR 2188/4885TDP1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.